CJC-1295 calculator
A GHRH analog discussed in growth hormone secretagogue protocols, frequently paired with ipamorelin.
Also known as: Modified GRF (1-29), CJC-1295 no DAC
FDA status — not an approved drug Not FDA-approved for any use. CJC-1295 was placed in Category 2 of FDA's bulk drug substances list. Prohibited in sport by WADA.
Schedule CJC-1295 → Set your dosing schedule and get a phone notification when each dose is due. Free.
What CJC-1295 is
CJC-1295 is a modified analog of growth hormone releasing hormone. It is usually discussed alongside ipamorelin because the two act on different receptors, and community protocols often pair them for that reason.
Research depth: 3/5 Preclinical work plus small human pharmacokinetic studies showing sustained GH and IGF-1 elevation; development was discontinued. Human trials: Small PK studies. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How CJC-1295 works
It binds GHRH receptors in the pituitary to stimulate growth hormone release. The DAC version attaches to albumin in the blood, extending its half-life to roughly a week; the no-DAC form (modified GRF 1-29) clears in hours, which is why the two are dosed on completely different schedules.
CJC-1295 side effects
Commonly reported
- Injection-site reactions
- Flushing and headache
- Water retention and joint aches
- Tingling or numbness in the hands
Serious — seek medical care
- Sustained elevation of GH and IGF-1 with the DAC form, which raises insulin resistance concerns
- Development was discontinued after a safety event in one trial
- Prohibited in sport by WADA
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.5 mg/mL. A 100 mcg dose is then 0.04 mL — about 4 units on a 100-unit insulin syringe, giving roughly 50 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable CJC-1295 dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for CJC-1295 run from 100 mcg to 300 mcg. Reference figures from community protocols. Formulations with and without DAC are dosed on very different schedules.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use CJC-1295 at all are decisions for a licensed clinician who knows your history.
Common questions
What is the difference between CJC-1295 with and without DAC?
The DAC (drug affinity complex) version has a much longer half-life and is described on a weekly schedule, while the no-DAC form is described on a daily one. Neither is FDA-approved. The reconstitution arithmetic is the same for both.
How much water for a 5 mg CJC-1295 vial?
2 mL gives 2.5 mg/mL, which places a 100 mcg dose at 4 units on a 100-unit insulin syringe. Some people use less water to reduce injection volume, others use more to make small doses easier to read.